Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee

Inclusion Criteria: * Age \> 18 years of age * Diagnosed with osteoarthritis of the knee * Candidate for an intra-articular injection (single joint, unilateral) of Monovisc® or Cingal® as part of their routine clinical care and in accordance with the locally approved label Exclusion Criteria: * Previous intra-articular injection within the last 6 months from enrolment * Known hypersensitivity to cortico-steroids, hyaluronic acid or any component of Cingal® or Monovisc® * Infectious, traumatic or neoplasic component of knee pathology * Surgery of the knee within the last 6 months or scheduled surgery in the next two months from enrolment * Patients with impaired cardio-renal function, endocrine, or other diseases or conditions that use of corticosteroid is warned. * Patients with known bleeding disorders * Patient currently treated with oral steroids or opioids * Patients that, in the investigators' opinion, are unlikely to comply with protocol * Pregnant or nursing women or women who suspect they might be pregnant.